In a non-randomized phase II trial enrolling 28 adults with Philadelphia-chromosome-positive (Ph+) B-ALL, dasatinib was administered as part of the induction regimen, followed by sequential CD19 and CD22 CAR T-cells, and this was continued as maintenance. Here, CD19 is linked to acute lymphoblastic leukemia.